Terapia antitrombotica nei pazienti sottoposti a impianto transcatetere di valvola aortica
View Full Paper
Ask AI
Bookmark
Share
Key result
DAPT post-TAVI increases bleeding without ischemic benefit over aspirin alone, while OAC may prevent valve thrombosis.
Why the study?
Bleeding and cerebral ischemic events are frequent complications after TAVI, and the optimal antithrombotic therapy to manage these patients remains uncertain.
What is the optimal antithrombotic therapy in patients undergoing transcatheter aortic valve implantation?
Structured PICO
What is the optimal antithrombotic therapy in patients undergoing transcatheter aortic valve implantation?
P
Population
Patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).
I
Intervention
Antithrombotic therapy (including dual antiplatelet therapy, aspirin alone, or oral anticoagulants)
While guidelines support DAPT after TAVI, recent evidence suggests aspirin alone may reduce bleeding without compromising efficacy, and oral anticoagulants may be needed to prevent valve thrombosis.
Limitations
- Scarcity of dedicated large randomized clinical trials
- Heterogeneity in current international guideline recommendations
- Underestimation of clinical bioprosthetic valve thrombosis
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
May support aspirin monotherapy post-TAVI to reduce bleeding; leaves open anticoagulation's role in preventing valve thrombosis pending RCTs.
Cite This Study
Gargiulo et al. (2016) conducted a review in Severe aortic stenosis. Antithrombotic therapy was evaluated. Current evidence suggests dual antiplatelet therapy after TAVI may increase bleeding without ischemic benefit compared to aspirin alone, while oral anticoagulation may prevent valve thrombosis.
Topics
View Full Paper
Ask AI
Bookmark
Share